Mirxes Holding Company Limited announced it has completed enrolment in CADENCE CRC, a prospective clinical study designed to validate its blood-based colorectal cancer screening test in average- and high-risk adults. The registrational study enrolled more than 6,000 participants across Southeast Asia, with colonoscopy used as the reference method. The company said the study is now moving into final laboratory analysis and data evaluation, and expects to report topline results in 2026. Mirxes also stated that, subject to successful outcomes and regulatory requirements, it plans to initiate commercialisation of the test as a laboratory developed test in Singapore and selected Southeast Asia markets by mid-2026 while seeking IVD regulatory approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260223-12027579), on February 23, 2026, and is solely responsible for the information contained therein.